337 related articles for article (PubMed ID: 9561345)
1. Glimepiride. A review of its use in the management of type 2 diabetes mellitus.
Langtry HD; Balfour JA
Drugs; 1998 Apr; 55(4):563-84. PubMed ID: 9561345
[TBL] [Abstract][Full Text] [Related]
2. The effect of glimepiride on pancreatic beta-cell function under hyperglycaemic clamp and hyperinsulinaemic, euglycaemic clamp conditions in non-insulin-dependent diabetes mellitus.
Clark HE; Matthews DR
Horm Metab Res; 1996 Sep; 28(9):445-50. PubMed ID: 8911981
[TBL] [Abstract][Full Text] [Related]
3. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
[TBL] [Abstract][Full Text] [Related]
4. Clinical profile of glimepiride.
Draeger E
Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S139-46. PubMed ID: 8529506
[TBL] [Abstract][Full Text] [Related]
5. Short-term comparison of once- versus twice-daily administration of glimepiride in patients with non-insulin-dependent diabetes mellitus.
Sonnenberg GE; Garg DC; Weidler DJ; Dixon RM; Jaber LA; Bowen AJ; DeChemey GS; Mullican WS; Stonesifer LD
Ann Pharmacother; 1997 Jun; 31(6):671-6. PubMed ID: 9184703
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl): a double-blind comparison with glibenclamide.
Draeger KE; Wernicke-Panten K; Lomp HJ; Schüler E; Rosskamp R
Horm Metab Res; 1996 Sep; 28(9):419-25. PubMed ID: 8911976
[TBL] [Abstract][Full Text] [Related]
7. Clinical profile of the novel sulphonylurea glimepiride.
Rosskamp R; Wernicke-Panten K; Draeger E
Diabetes Res Clin Pract; 1996 Jul; 31 Suppl():S33-42. PubMed ID: 8864639
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of insulin and sulfonylurea combination therapy in type II diabetes. A meta-analysis of the randomized placebo-controlled trials.
Johnson JL; Wolf SL; Kabadi UM
Arch Intern Med; 1996 Feb; 156(3):259-64. PubMed ID: 8572835
[TBL] [Abstract][Full Text] [Related]
9. Extrapancreatic effects of sulfonylureas--a comparison between glimepiride and conventional sulfonylureas.
Müller G; Satoh Y; Geisen K
Diabetes Res Clin Pract; 1995 Aug; 28 Suppl():S115-37. PubMed ID: 8529504
[TBL] [Abstract][Full Text] [Related]
10. Continuous versus intermittent sulphonylurea therapy in non-insulin-dependent diabetes mellitus.
Grunberger G
Drug Saf; 1993 Oct; 9(4):249-53. PubMed ID: 8260118
[TBL] [Abstract][Full Text] [Related]
11. Effects of the combination of insulin and glibenclamide in type 2 (non-insulin-dependent) diabetic patients with secondary failure to oral hypoglycaemic agents.
Stenman S; Groop PH; Saloranta C; Tötterman KJ; Fyhrqvist F; Groop L
Diabetologia; 1988 Apr; 31(4):206-13. PubMed ID: 3133266
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment.
Rosenkranz B; Profozic V; Metelko Z; Mrzljak V; Lange C; Malerczyk V
Diabetologia; 1996 Dec; 39(12):1617-24. PubMed ID: 8960852
[TBL] [Abstract][Full Text] [Related]
13. Sulphonylurea therapy doubles B-cell response to glucose in type 2 diabetic patients.
Hosker JP; Burnett MA; Davies EG; Harris EA; Turner RC
Diabetologia; 1985 Nov; 28(11):809-14. PubMed ID: 3936738
[TBL] [Abstract][Full Text] [Related]
14. Sulphonylurea antidiabetic drugs. An update of their clinical pharmacology and rational therapeutic use.
Melander A; Bitzén PO; Faber O; Groop L
Drugs; 1989 Jan; 37(1):58-72. PubMed ID: 2651086
[TBL] [Abstract][Full Text] [Related]
15. Oral antihyperglycaemics. Considerations in older patients with non-insulin-dependent diabetes mellitus.
Jennings PE
Drugs Aging; 1997 May; 10(5):323-31. PubMed ID: 9143853
[TBL] [Abstract][Full Text] [Related]
16. Comparative tolerability profiles of oral antidiabetic agents.
Krentz AJ; Ferner RE; Bailey CJ
Drug Saf; 1994 Oct; 11(4):223-41. PubMed ID: 7848543
[TBL] [Abstract][Full Text] [Related]
17. Glimepiride-induced prevention of diabetes and autoimmune events in the BB rat: revised.
Cheta DM; Lim J; Chan EK; Kunakorn T; Charles MA
Life Sci; 1995; 57(24):2281-90. PubMed ID: 7475982
[TBL] [Abstract][Full Text] [Related]
18. Glibenclamide improves the response to insulin treatment in non-insulin-dependent diabetics with second failure to sulfonylurea therapy.
Lins PE; Lundblad S; Persson-Trotzig E; Adamson U
Acta Med Scand; 1988; 223(2):171-9. PubMed ID: 3126626
[TBL] [Abstract][Full Text] [Related]
19. Combination of oral antidiabetic drugs and insulin in the treatment of non-insulin-dependent diabetes.
Scheen AJ; Castillo MJ; Lefèbvre PJ
Acta Clin Belg; 1993; 48(4):259-68. PubMed ID: 8212978
[TBL] [Abstract][Full Text] [Related]
20. Effect of an alpha-glucosidase inhibitor combined with sulphonylurea treatment on glucose metabolism in patients with non-insulin-dependent diabetes mellitus.
Okada S; Ishii K; Tanokuchi S; Hamada H; Ichiki K; Ota Z
J Int Med Res; 1995; 23(4):279-83. PubMed ID: 7589771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
